2021 FDA approvals for lung cancer treatment
Eugene Manley, Jr., PhD, LCRF’s Director of Scientific Programs, compiled the following list of FDA drug approvals for lung cancer treatment taking place in 2021. The associated companion diagnostics have been included where applicable. “Companion diagnostics are devices, tests, or imaging tools that provide information essential to the use of the therapeutic product,” Dr. Manley explained. “In general, they are associated with detecting mutations and are necessary for optimally selecting treatment for patients.”
IASLC World Conference on Lung Cancer Recap
The International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer (WCLC 2021) took place September 8-14, drawing over 6,000 registrants from more than 500 countries. WCLC is the only global network dedicated solely to the study of lung cancer and other thoracic malignancies, and the meeting featured many updates in NSCLC, SCLC, immunotherapy, combination therapies, disparities, clinical trials, and other diseases associated with lung cancer.
Findings and developments in the lung cancer space during early 2021
A number of interesting developments in the lung cancer research space have taken place in 2021 so far. Several new findings were introduced at the American Association for Cancer Research (AACR) and American Society for Clinical Oncology (ASCO) annual meetings as well as the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer.
Read a mid-year update with commentary from LCRF’s director of scientific programs Eugene Manley, Jr., PhD, and Kathryn Gold, MD, LCRF’s guest for our #TogetherSeparately Lung Cancer Mid-Year Update webinar.
Research developments
- Teliso-V granted FDA Breakthrough Designation for NSCLC
- 2021 FDA approvals for lung cancer treatment
- Dr. Herbst outlines progress in lung cancer treatment
- Dr. Loretta Erhunmwunsee
- Dr. Nikhil Joshi
- SCLC molecular atlas could lead to potential new therapies
- FDA approves atezolizumab for stage II to IIIA lung cancer
- IASLC World Conference on Lung Cancer Recap
- Researchers leverage fibroblasts to enhance personalized treatment for lung cancer patients
Recent FDA approvals
- Teliso-V granted FDA Breakthrough Designation for NSCLC
- 2021 FDA approvals for lung cancer treatment
- FDA approves atezolizumab for stage II to IIIA lung cancer
- FDA approves mobocertinib for EGFR exon 20 insertion+ NSCLC
- Findings and developments in the lung cancer space during the first half of 2021
- #TogetherSeparately Live Talk on recent FDA approvals